Kavuru Vimal 4

4 · Acasti Pharma Inc. · Filed Sep 27, 2023

Form 4

Period: 2023-09-25

Director

Transactions

Purchase
Common Shares
2023-09-25$1.85/sh+676,371$1,249,934→ 1,188,076 total(indirect: See footnote)
Purchase
Common Warrants (right to buy)
2023-09-25$0.13/sh+422,732$52,842→ 422,732 total(indirect: See footnote)
Exercise: $3.00From: 2023-09-25→ Common Shares (422,732 underlying)

Holdings

Footnotes (5)

[F1]These indirect holdings have been adjusted to give effect to the Company's 1-for-6 reverse stock split, effective July 10, 2023.
[F2]These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member.
[F3]Shares are held directly by Kottayil Grace Pharma LLC, of which Vimal Kavuru is a Manager. Mr. Kavuru is a Manager of Kottayil Grace Pharma LLC and shares voting and dispositive power with respect to the shares of Acasti Pharma Inc. directly held by Kottayil Grace Pharma LLC.
[F4]The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder and certain other related parties, would not beneficially own after any such exercise more than 19.99% of the then issued and outstanding common shares of the Company (the "Blocker"). Due to the Blocker, the Common Warrants beneficially owned indirectly by the holder are only currently partially exercisable.
[F5]The Common Warrants will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) September 25, 2028.

Documents

1 file